Format

Send to

Choose Destination
Biol Aujourdhui. 2019;213(1-2):59-64. doi: 10.1051/jbio/2019021. Epub 2019 Jul 5.

[New horizons for acute and prophylactic treatments of migraine].

[Article in French]

Author information

1
Service de Neurochirurgie, Hôpital Pitié-Salpétrière, 75013 Paris, France.

Abstract

The current treatment of migraine attacks is triptans and NSAIDs, but the calcitonin gene-related peptide (CGRP) has emerged as a key neuropeptide target for migraine therapy. Despite an off target class effect on liver enzymes, two CGRP receptor antagonists, ubrogepant and rimegepant, remain in development, together with a 5-HT1F receptor agonist (lasmiditan), for which cardiovascular contraindications that limit the utility of triptans do not exist. Importantly, to avoid an excessive use of acute medication with the risk of medication overuse, prophylactic therapeutics are the best choice. To date, monoclonal antibodies which block CGRP actions are on the market all over the world but not yet in France. The research is very active in different directions and targets notably hypothalamic neuropeptides because the hypothalamus hosts many key neuropeptide systems that seem to play a role in migraine physiopathology. These neuropeptides include orexins, oxytocin, neuropeptide Y (NPY) and pituitary adenylate cyclase-activating polypeptide (PACAP). In addition, other promising drugs for the treatment of migraine are nitric oxide synthase inhibitors and acid-sensing ion channel (ASIC) blockers.

PMID:
31274104
DOI:
10.1051/jbio/2019021

Supplemental Content

Loading ...
Support Center